SCHEMBL23970635

SCHEMBL23970635

O=C(OCCCCF)c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.81
LMNA P02545 2/20 0.59
MAPK1 P28482 2/20 0.52
HIF1A Q16665 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
TSHR P16473 2/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
F2 P00734 1/20 0.47
CNR2 P34972 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17459902 0.94 TDP1 (0.78) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL223441 0.90 TDP1 (1.00) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL225815 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL17466182 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL11896606 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL2069111 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL223238 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL11896235 0.88 TDP1 (0.96) TDP1LMNAMAPK1HIF1ASLC6A2
Ammonia Solution, Strong SCHEMBL2530225 0.86 TDP1 (0.92) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL10458171 0.86 TDP1 (0.70) TDP1LMNAMAPK1HIF1ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed
CN-104114537-A Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection ASTEX THERAPEUTICS LTD 2014-10-22 CN disclosed